PDL BioPharma Issues Downbeat Q3 Revenue Forecast

Lisa Levin , Benzinga Staff Writer

September 08, 2011 7:58am Comments

PDL BioPharma Inc (NASDAQ: PDLI) projected downbeat third-quarter revenue.

PDL BioPharma now projects Q3 revenue of $83 million, versus analysts' estimates of $88 million.

PDL BioPharma shares gained 0.17% to $5.80 in after-hours trading.

Posted-In: guidance News Guidance

1	HAHC, NEM: US Stocks Hit New Highs As Magnificent Seven Reach $19 Trillion: What&#...
2	$ETH, $BTC: Bitcoin Could See Bearish August, Analyst Says—What Does It...
3	GOOG, PSX: Dow Dips Over 300 Points Amid Alphabet, Tesla Earnin...
4	IONQ, HIMS: Benzinga's 'Stock Whisper'...
5	$SOL, $BTC: Anthony Scaramucci May Not Have...
6	NOX, LHX: Trump's $151 Billio...
7	MRK, ARKG: Palantir, Nvidi...

1	$BTC: Scams, Lost Keys, and Forgotten Wallets: The Bitcoin Whisperer Who Brings Cr...
2	Exiled Iranian Prince Reza Pahlavi Claims 50,000 Defectors Have Joined His M...
3	META: Mark Zuckerberg's Meta Platforms Dodges $8 Billion Trial With Eleve...
4	'She Just Does What She Wants With It': Disabled Man Says Mom...
5	Robert Kiyosaki Says ETFs Are Like Pictures of Guns, Real Assets Are Better
6	Federal Government Becomes Major Investor Under Donald Trump, Echoing Wa...
7	New Jersey US Attorney Fired After Being Chosen Over Former Trump Lawyer...

Market Overview